ADARx Pharmaceuticals’ recent IPO filing sets terms for a $350 million raise at $15–17 per share, implying a fully diluted valuation near $1.74 billion at the midpoint, with AbbVie committing up to $100 million in a concurrent private placement for a roughly 4.9% post-IPO stake. Trader sentiment remains balanced across market-cap buckets because the final pricing, share count after overallotment, and immediate post-listing trading dynamics are still fluid, while the company’s siRNA pipeline—led by Phase 3 onvuzosiran for hereditary angioedema—carries both clinical and regulatory milestones that could shift perceived value. Strong institutional interest and an existing AbbVie collaboration worth up to $8 billion in milestones provide support, yet pre-revenue status and broader biotech IPO volatility keep multiple closing-cap outcomes equally plausible ahead of the expected late-September debut.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว$3B+ 26%
$1.5B-$1.75B 25%
$1.75B-$2B 25%
<$1.5B 25%
ใหม่
ใหม่
Sep 25, 2026
<$1.5B
25%
$1.5B-$1.75B
25%
$1.75B-$2B
25%
$2B-$2.25B
25%
$2.25B-$2.5B
24%
$2.5B-$3B
25%
$3B+
26%
No IPO before November 2026
25%
$3B+ 26%
$1.5B-$1.75B 25%
$1.75B-$2B 25%
<$1.5B 25%
ใหม่
ใหม่
Sep 25, 2026
<$1.5B
$0 ปริมาณ
25%
$1.5B-$1.75B
$0 ปริมาณ
25%
$1.75B-$2B
$0 ปริมาณ
25%
$2B-$2.25B
$0 ปริมาณ
25%
$2.25B-$2.5B
$0 ปริมาณ
24%
$2.5B-$3B
$0 ปริมาณ
25%
$3B+
$0 ปริมาณ
26%
No IPO before November 2026
$0 ปริมาณ
25%
This market will resolve based on ADARx's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on September 24 (ET). If no such IPO occurs by October 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before November 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.ADARx Pharmaceuticals’ recent IPO filing sets terms for a $350 million raise at $15–17 per share, implying a fully diluted valuation near $1.74 billion at the midpoint, with AbbVie committing up to $100 million in a concurrent private placement for a roughly 4.9% post-IPO stake. Trader sentiment remains balanced across market-cap buckets because the final pricing, share count after overallotment, and immediate post-listing trading dynamics are still fluid, while the company’s siRNA pipeline—led by Phase 3 onvuzosiran for hereditary angioedema—carries both clinical and regulatory milestones that could shift perceived value. Strong institutional interest and an existing AbbVie collaboration worth up to $8 billion in milestones provide support, yet pre-revenue status and broader biotech IPO volatility keep multiple closing-cap outcomes equally plausible ahead of the expected late-September debut.
This market will resolve based on ADARx's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on September 24 (ET). If no such IPO occurs by October 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before November 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on September 24 (ET). If no such IPO occurs by October 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before November 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
ตลาดเปิดเมื่อ: Sep 23, 2026, 6:43 PM ET
ปริมาณการซื้อขาย
$0วันสิ้นสุด
Sep 25, 2026ตลาดเปิดเมื่อ
Sep 23, 2026, 6:43 PM ETผู้ตัดสินผล
0x69c47de9d...This market will resolve based on ADARx's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on September 24 (ET). If no such IPO occurs by October 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before November 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.ADARx Pharmaceuticals’ recent IPO filing sets terms for a $350 million raise at $15–17 per share, implying a fully diluted valuation near $1.74 billion at the midpoint, with AbbVie committing up to $100 million in a concurrent private placement for a roughly 4.9% post-IPO stake. Trader sentiment remains balanced across market-cap buckets because the final pricing, share count after overallotment, and immediate post-listing trading dynamics are still fluid, while the company’s siRNA pipeline—led by Phase 3 onvuzosiran for hereditary angioedema—carries both clinical and regulatory milestones that could shift perceived value. Strong institutional interest and an existing AbbVie collaboration worth up to $8 billion in milestones provide support, yet pre-revenue status and broader biotech IPO volatility keep multiple closing-cap outcomes equally plausible ahead of the expected late-September debut.
This market will resolve based on ADARx's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on September 24 (ET). If no such IPO occurs by October 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before November 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on September 24 (ET). If no such IPO occurs by October 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before November 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
ปริมาณการซื้อขาย
$0วันสิ้นสุด
Sep 25, 2026ตลาดเปิดเมื่อ
Sep 23, 2026, 6:43 PM ETผู้ตัดสินผล
0x69c47de9d...ADARx Pharmaceuticals’ recent IPO filing sets terms for a $350 million raise at $15–17 per share, implying a fully diluted valuation near $1.74 billion at the midpoint, with AbbVie committing up to $100 million in a concurrent private placement for a roughly 4.9% post-IPO stake. Trader sentiment remains balanced across market-cap buckets because the final pricing, share count after overallotment, and immediate post-listing trading dynamics are still fluid, while the company’s siRNA pipeline—led by Phase 3 onvuzosiran for hereditary angioedema—carries both clinical and regulatory milestones that could shift perceived value. Strong institutional interest and an existing AbbVie collaboration worth up to $8 billion in milestones provide support, yet pre-revenue status and broader biotech IPO volatility keep multiple closing-cap outcomes equally plausible ahead of the expected late-September debut.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว
ระวังลิงก์ภายนอก
ระวังลิงก์ภายนอก
คำถามที่พบบ่อย